In fragment-based drug discovery, low molecular weight hits are identified in high throughput screens, such as in the XChem facility at the Diamond Light Source with which I collaborate, and subsequently elaborated into larger compounds leveraging the premise that analogues bind in a similar manner. Previously, I developed Fragmenstein, a tool that mergers and places compounds by stitching the template molecules together to create a monster conformer requiring energy minimisation. This approach has spawned several derived methods, which I apply in the hit elaboration part of the ASAP consortium (https://asapdiscovery.org/) to create novel antivirals.